Palforzia Pregnancy Warnings
Animal studies are not available. There are no controlled data in human pregnancy. The background birth defect and miscarriage risk for the indicated population is not known. In the US general population, the estimated major birth defect risk is 2 to 4% and the miscarriage risk is 15 to 20%.
A pregnancy registry monitoring outcomes of exposures during pregnancy is available. Healthcare providers are encouraged to contact Aimmune at 1-833-246-2566.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
The manufacturer makes no recommendation regarding use during pregnancy.
US FDA pregnancy category: Not assigned
Comments:
-Anaphylaxis may occur from accidental peanut exposure in peanut-allergic patients.
-This drug may cause anaphylaxis.
-Anaphylaxis may cause dangerous hypotension, which may compromise placental perfusion, causing significant risk to the fetus.
See references
Palforzia Breastfeeding Warnings
The manufacturer makes no recommendation regarding use during lactation.
Excreted into human milk: Data not available
Excreted into animal milk: Data not available
Comments:
-There is no information regarding this drug on the presence in human milk, the effects on a breastfed infant, or effects on milk production.
-Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for this medication as well as any potential adverse effects from this drug or the underlying maternal condition.
See references